ICYMI: 2019 brings innovative medicines to patients

New reports from the U.S. Food and Drug Administration (FDA) show a total of 56 novel new medicines were approved in 2019. Among these,48 were approved by the Center for Drug Evaluation and Research (CDER) and 8 were approved by the Center for Biologics Evaluation and Research (CBER). While medicine approval numbers vary each year, 2019 saw exciting advancements in drug development. These strong approval figures demonstrate biopharmaceutical companies ’ unwavering commitment to developing innovative treatments for patients, offering hope for improved health outcomes. 2019 also highlights continued success of thePrescription Drug User Fee Act (PDUFA) program that helps ensure timely and effective review of new drug applications (NDA). FDA ’s CDER noted they “met or exceeded almost every PDUFA goal date for application review agreed to with the pharmaceutical industry and approved by Congress.”
Source: The Catalyst - Category: Pharmaceuticals Tags: Research and Development FDA PDUFA New Era of Medicine & D Focus Source Type: news